Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Cannabis
Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Isodiol International Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by HonestAbeon Dec 20, 2017 1:07pm
146 Views
Post# 27197402

RE:RE:Disappointing

RE:RE:DisappointingI am saying I am disappointed in management selling out at such cheap discounts to cater to the whims of certain high profile individuals. ISOL realistically could have issued a brokered PP deal at $1.50 open to joe public and easily raised the $20m or $30m they wanted, and without any warrants. Demand and interest for this company is suddenly there and they have an interesting story to sell. No need to unnecessarily dilute so excessively to the detriment of shareholders. When all the smoke clears in the next year ISOL will end up closer to 400M shares outstanding fully diluted, which dramatically lowers the maximum potential upside.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities